adg116,toripalimab
junshi biosciences,adagene,coherus
['ease,(-please),(-disease),(-incrrease),(-decrease)', 'adg116 ', 'adagene']
today we announced data at #sitc2022 showing how targeting a unique and highly conserved epitope of ctla-4 with our neobody technology translates into differentiated safety and efficacy for our adg116 anti-ctla-4 candidate. read the release here: 